Shenzhen Kangtai Biological Products Yönetim

Yönetim kriter kontrolleri 2/4

Shenzhen Kangtai Biological Products CEO'su Xiang Miao, Dec2021 tarihinde atandı, in görev süresi 2.92 yıldır. şirketin hisselerinin 0.17% doğrudan sahiptir ve bu hisselerin değeri CN¥ 35.88M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.9 yıl ve 12.2 yıldır.

Anahtar bilgiler

Xiang Miao

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.9yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	2.9yrs
Yönetim Kurulu ortalama görev süresi	12.2yrs

Son yönetim güncellemeleri

Recent updates

CEO

Xiang Miao (51 yo)

2.9yrs

Görev süresi

CN¥3,337,100

Tazminat

Mr. Xiang Miao has been President at Shenzhen Kangtai Biological Products Co., Ltd. since December 29, 2021 and serves as its Director and served as its Vice President and Secretary.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hui Zhou	Chief Financial Officer	2.9yrs	CN¥1.37m	0.012% CN¥ 2.6m
Xiang Miao	President & Non-Independent Director	2.9yrs	CN¥3.34m	0.17% CN¥ 35.9m
Jiankai Liu	VP & Non-Independent Director	2.9yrs	CN¥3.40m	0.16% CN¥ 34.0m
Jin Tao	Board Secretary	2.9yrs	CN¥955.50k	0.014% CN¥ 2.9m

2.9yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim: 300601 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xiang Miao	President & Non-Independent Director	no data	CN¥3.34m	0.17% CN¥ 35.9m
Jiankai Liu	VP & Non-Independent Director	16.2yrs	CN¥3.40m	0.16% CN¥ 34.0m
Weimin Du	Chairman of the Board	16.2yrs	CN¥3.51m	25.5% CN¥ 5.4b
Zhiyun Lu	Chairman of the Supervisory Board	12.2yrs	Veri yok	0.038% CN¥ 8.0m
Hak Ping Wu	Independent Director	2.9yrs	CN¥112.50k	Veri yok
Feidong Wen	Vice Chairman	2.9yrs	CN¥2.11m	0.0081% CN¥ 1.7m

12.2yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300601 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 12.2 yıldır).

Shenzhen Kangtai Biological Products Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

Less than half of directors are independent

Insufficient new directors

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.17 in 3Q 2023)

Investor sentiment deteriorates as stock falls 22%

New minor risk - Share price stability

Shenzhen Kangtai Biological Products Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 27%

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.099 (vs CN¥0.28 in 2Q 2023)

Shenzhen Kangtai Biological Products Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Shenzhen Kangtai Biological Products Co., Ltd. Announces Dividend Implementation (Cash Only) Payable on 14 June 2024

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.18 in 1Q 2023)

Shenzhen Kangtai Biological Products Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 17%

Shenzhen Kangtai Biological Products Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.074 in 3Q 2022)

Shenzhen Kangtai Biological Products Co., Ltd. Announces Interim Profit Distribution Plan to Be Implemented (A Shares) for 2023, Payable on 13 October 2023

Shenzhen Kangtai Biological Products Co., Ltd. Approves 2023 Interim Cash Dividend

Shenzhen Kangtai Biological Products Co., Ltd. Proposes Interim Cash Dividend for the First Half of 2023

Second quarter 2023 earnings released: EPS: CN¥0.28 (vs CN¥0.14 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.25 in 1Q 2022)

Third quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.64 in 3Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Second quarter 2022 earnings released: CN¥0.53 loss per share (vs CN¥0.28 profit in 2Q 2021)

Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) announces an Equity Buyback for CNY 200 million worth of its shares.

Shenzhen Kangtai Biological Products Co., Ltd. Announces Final Cash Dividend for the Year 2021, Payable on 2 June 2022

Shenzhen Kangtai Biological Products Co., Ltd. Approves Final Cash Dividend for the Year 2021

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.037 in 1Q 2021)

Insufficient new directors

Now 22% undervalued after recent price drop

Full year 2021 earnings released: EPS: CN¥1.88 (vs CN¥1.03 in FY 2020)

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥1.02 (vs CN¥0.26 in 3Q 2020)

Insufficient new directors

Second quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.39 in 2Q 2020)

Shenzhen Kangtai Biological Products Co., Ltd. Announces Philippine Food and Drug Administration Approval to BIOKANGTAI COVID-19 Vaccine for Phase III Clinical Trial in the Philippines

Phase III Clinical Fieldwork of the Inactivated COVID-19 Vaccine (Vero Cells) Independently Developed and Manufactured by Shenzhen Kangtai Biological Products Co., Ltd. is Officially Initiated in Malaysia

Shenzhen Kangtai Biological Products Co., Ltd. Not to Pay Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.037 (vs CN¥0.004 in 1Q 2020)

New 90-day low: CN¥135

New 90-day high: CN¥181

New 90-day low: CN¥149

Third quarter earnings released

New 90-day low: CN¥157

New 90-day high - CN¥227

Shenzhen Kangtai Biological Products Co., Ltd. to Report First Half, 2020 Results on Jul 21, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş